Incyte price target lowered to $81 from $82 at Citi

Citi lowered the firm’s price target on Incyte to $81 from $82 and keeps a Buy rating on the shares. The company’s Q4 Jakafi revenue came in-line, with Opzelura up 19% quarter-over-quarter driven by refills and better access, the analyst tells investors in a research note. The firm says that despite competition, Jakafi myelofibrosis market share remains stable.